EKEmily N. Kukan

Emily N. Kukan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily N. Kukan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endothelial cells sialylate IgG within the FcRn-mediated recycling pathway

    by Leandre M. Glendenning, Megan D. Long, Gracie C. Carlson, Austin D. Silva, Siyu Wang, Kalob M. Reynero, Emily N. Kukan, Susan L. Bellis, Wendy A. Goodman, Brian A. Cobb

    IgG is a key to adaptive immunity and a critical platform for drug design. Sialic acid on the conserved glycan within the Fc domain is believed to promote anti-inflammatory IgG function; however, regulation of sialylation remains poorly defined. We previously showed that IgG sialylation is primarily mediated by B cell–extrinsic processes in mice. Here, we found that IgG sialylation occurs in the subcellular compartments of the FcRn-mediated IgG recycling pathway of endothelial cells. This process is down-regulated by inflammatory signals and up-regulated during gestation, providing mechanistic insight into the epidemiology associating IgG glycosylation, pregnancy and inflammatory disease. These findings demonstrate that plasma-localized IgG glycosylation is dynamically altered by the endothelium, revealing a potential mechanism through which the function of all endogenous and administered IgG and Fc-containing pharmaceuticals could be altered.


  • Ablation of CD22 induces a pro-inflammatory transcriptome shift and endocytic deficits in M2-like macrophages

    by Emily N Kukan, Gabrielle L Fabiano, Julie Y Zhou, Ava R Richard, Kevin A Telfer, Brian A Cobb

    The interactions between environmental glycans and glycan-binding proteins modulate a host of processes across biological systems. The Siglec/sialic acid axis has gained increasing attention as an immunologic checkpoint due to its involvement with reducing inflammatory processes and promoting tumor growth. Siglec-2, or CD22, has been extensively characterized as a co-receptor for the B cell receptor (BCR) and is critical for the prevention of self-reactive B cell responses through its recognition of α2,6-linked sialic acids. More recently, CD22 has emerged as an important receptor for macrophage biology. Here, we investigate the consequences of genetic ablation of CD22 in murine macrophages (CD22KO). Aged CD22KO mice developed a fatty liver phenotype similar to that seen in aged animals lacking hepatocyte α2,6-sialylation (HcKO). CD22KO bone marrow-derived macrophages (BMDMs) exhibited few differences in canonical markers of M1-like and M2-like polarization, but M2-like CD22KO BMDMs showed a pro-inflammatory shift in transcriptome and a reduction in endocytic and efferocytotic capacity. These data suggest that CD22 in murine M2-like macrophages is strongly associated with a homeostatic transcriptional profile and directly participates in immunologically silent housekeeping functions such as clearance of sialylated-self debris through the Siglec-sialic acid axis.


  • M2 ‐Like Macrophages Exhibit Sialic Acid‐Enhanced Efferocytosis via the Siglec CD22

    by Emily N. Kukan, Gabrielle L. Fabiano, Leandre M. Glendenning, Julie Y. Zhou, Kevin A. Telfer, James C. Paulson, Brian A. Cobb

    The sialic acid/Siglec axis is an important immunologic regulatory pathway in which host‐specific α2,6‐sialylated glycans are recognized as markers of self. CD22, known primarily as a surface receptor on B cells, directly prevents autoantigen responses through concurrent recognition of α2,6‐linked sialic acids. Here, we report that CD22 is expressed in macrophages polarized to an M2‐like, immunomodulatory phenotype. Tissue‐resident macrophage populations classically showing an M2‐like skew, such as in the lung, were found to be significantly enriched for CD22 expression. We also discovered that CD22 promotes efferocytosis of sialylated glycoproteins and apoptotic debris and is associated with increased protein processing but reduced T cell activation. These findings support a model whereby CD22 + M2‐like macrophages participate in the resolution of inflammation and a return to tissue homeostasis via the clearance of host‐derived α2,6‐sialylated debris, degrading this material without further exacerbation of T cell‐mediated inflammation.


  • Glyco You Should Know

    by Emily Kukan

    Emily Kukan; Glyco You Should Know, Glycobiology, , cwae022, https://doi.org/10.1093/glycob/cwae022

  • Open Access

    IgG sialylation occurs via the FcRn-mediated recycling pathway in endothelial cells

    by Leandre M. Glendenning, Kalob M. Reynero, Emily N. Kukan, Megan D. Long, Brian A. Cobb

    IgG is a key mediator of immune responses throughout the human body, and the structure of the conserved glycan on the Fc region has been identified as a key inflammatory switch regulating its downstream effects. In particular, the absence of terminal sialic acid has been shown to increase the affinity of IgG for activating Fc receptors, cascading the inflammatory response in a variety of diseases and conditions. Previously, we have shown that IgG sialylation is mediated by B cell-extrinsic processes. Here, we show that the FcRn-mediated recycling pathway within endothelial cells is a critical modulator of IgG sialylation. Building a deeper understanding of how IgG sialylation is regulated will drive the development of novel therapeutics which dynamically tune IgG functionality in vivo . One-Sentence Summary: Endothelial cells remodel IgG glycans within the FcRn-mediated recycling pathway.


  • Open Access

    Platelet-Localized ST6Gal1 Does Not Impact IgG Sialylation

    by Leandre M. Glendenning, Julie Y. Zhou, Emily N. Kukan, Chao Gao, Richard D. Cummings, Smita Joshi, Sidney W. Whiteheart, Brian A. Cobb

    The IgG antibody class forms an important basis of the humoral immune response, conferring reciprocal protection from both pathogens and autoimmunity. IgG function is determined by the IgG subclass, as defined by the heavy chain, as well as the glycan composition at N297, the conserved site of N-glycosylation within the Fc domain. For example, lack of core fucose promotes increased antibody-dependent cellular cytotoxicity, whereas α2,6-linked sialylation by the enzyme ST6Gal1 helps to drive immune quiescence. Despite the immunological significance of these carbohydrates, little is known about how IgG glycan composition is regulated. We previously reported that mice with ST6Gal1-deficient B cells have unaltered IgG sialylation. Likewise, ST6Gal1 released into the plasma by hepatocytes does not significantly impact overall IgG sialylation. Since IgG and ST6Gal1 have independently been shown to exist in platelet granules, it was possible that platelet granules could serve as a B cell-extrinsic site for IgG sialylation. To address this hypothesis, we used a platelet factor 4 (Pf4)-Cre mouse to delete ST6Gal1 in megakaryocytes and platelets alone or in combination with an albumin-Cre mouse to also remove it from hepatocytes and the plasma. The resulting mouse strains were viable and had no overt pathological phenotype. We also found that despite targeted ablation of ST6Gal1, no change in IgG sialylation was apparent. Together with our prior findings, we can conclude that in mice, neither B cells, the plasma, nor platelets have a substantial role in homeostatic IgG sialylation.